We may earn money or products from the companies mentioned in this post.
Educational information only. This article does not replace medical advice, diagnosis, or treatment. Discuss treatment choices with a qualified healthcare professional.
Your periods are becoming unpredictable, you wake up soaked at 3 a.m., and a friend says hormones fixed everything for her while another says to stay far away from them. Both stories leave you with more questions than answers.
This guide offers a calm, plain-language look at hormone replacement therapy for perimenopause. It covers what the treatment is, what it may help, where the risks sit, and what to ask when you sit down with a clinician.
Your health history, symptoms, contraception needs, and preferences shape the discussion.
Can hormone therapy be considered during perimenopause?
Quick answer: Hormone therapy can be considered during perimenopause for bothersome symptoms after an individual clinical assessment. Menopausal hormone therapy is not contraception. The choice of systemic or local therapy, and whether endometrial protection is needed, depends on the treatment goal and your history.
Perimenopause is the transition leading up to menopause, often involving cycle changes and symptoms. Natural menopause is identified after 12 consecutive months without a period when another cause does not explain it. Hormonal contraception and procedures that stop bleeding can make that marker difficult to use.
The Menopause Society describes hormone therapy and other hormonal options for perimenopausal symptoms. You do not need to wait until symptoms become unbearable to ask for help.
Much of the major hormone-therapy trial evidence comes from postmenopausal populations. A finding from those trials cannot automatically be applied to someone who is still cycling or to a different formulation. Current ACOG guidance covers perimenopausal and postmenopausal individuals, while acknowledging differences in the quality of evidence for different symptoms.
For background, read when perimenopause starts and what to track. Our overview of treatment options covers the broader choices.
Symptoms it may help and symptoms needing separate evaluation
Systemic hormone therapy delivers hormones throughout the body. Its main symptom indication is bothersome hot flashes and night sweats. Some products also have indications related to vaginal symptoms or prevention of postmenopausal osteoporosis; the exact product label matters.
When vaginal dryness or painful sex is the main concern, a local treatment may be considered instead. Do not assume that systemic therapy is the appropriate treatment for every urinary complaint.
ACOG recommends suitable systemic therapy for hot flashes and sleep disturbance associated with those symptoms. Depression, anxiety, and worsening memory concerns need their own assessment. Hormone therapy should not replace appropriate depression treatment.
Several symptoms should never be written off as “just perimenopause” without a proper look:
- Very heavy bleeding, soaking through protection fast, or periods much longer than usual
- Bleeding between periods or after sex
- Fatigue that will not lift, which can come from thyroid problems or anemia
- Palpitations, chest pain, or shortness of breath
- Severe depression, panic, or difficulty functioning
- Brain fog that keeps getting worse
Ask what else could explain persistent symptoms and whether tests would change the plan. Routine hormone testing is not always useful; other tests may be appropriate for the symptoms and history. Sudden chest pain or shortness of breath needs emergency assessment rather than a routine menopause appointment.
Main options: systemic estrogen, progesterone/progestogens, and low-dose vaginal estrogen
Systemic estrogen
Systemic estrogen is the most effective treatment for hot flashes and night sweats. Delivery options include pills, patches, gels, sprays, and certain vaginal rings. A product used vaginally is not necessarily a low-dose local treatment.
Progesterone and progestogens
If you have a uterus, systemic estrogen generally requires an appropriate progestogen for endometrial protection. Certain approved combination therapies use a different protective approach; ask about the exact product rather than assuming every regimen is identical. Estrogen by itself can thicken the uterine lining and raise the risk of endometrial cancer.
Choices include micronized progesterone, which is a capsule chemically identical to the progesterone your body makes, along with synthetic progestins. A levonorgestrel IUD is sometimes used for this purpose too.
Use of a levonorgestrel intrauterine system for endometrial protection as part of hormone therapy is off-label in the United States. Ask which device is suitable and when it needs replacement for this purpose; contraceptive duration should not be assumed to establish the duration of endometrial protection.
Women who have had a hysterectomy usually do not need a progestogen.
Low-dose vaginal estrogen
Low-dose vaginal creams, tablets, inserts, and certain rings are designed mainly for local effects. They treat vaginal dryness, painful sex, and some urinary symptoms. They are not meant for hot flashes.
Systemic absorption is much lower with low-dose local products than with systemic therapy, but it is not necessarily zero. A progestogen is generally not required solely for low-dose vaginal estrogen; unexplained bleeding still requires assessment. Local therapy and systemic therapy carry different risk profiles, so studies of one should not be used to judge the other.
Anyone considering hormone replacement therapy for perimenopause should know which of the two a given study or headline is talking about.
Nonhormonal options
If hormones are unsuitable or unwanted, evidence-supported nonhormonal options exist. Our general treatment guide covers prescription and behavioral approaches, their limits, and drug-specific safety considerations. Nonhormonal does not mean risk-free.
Patches versus pills: practical differences and risk considerations
The route you choose changes how the hormone moves through your body. The table gives a simple side-by-side look.
| Feature | Skin (patch, gel, spray) | Oral pill |
|---|---|---|
| How it enters the body | Through the skin, bypassing the liver at first | Swallowed and processed by the liver first |
| Blood clot risk | Observational studies suggest lower risk | Linked to higher clot risk in studies |
| Practical use | Patches follow a product-specific schedule; gels and sprays usually need daily application | Usually taken daily; follow the exact label |
| Combination products | Some patches include a progestogen | Many combination pills exist |
| Good to know | Skin irritation, adhesion, and gel or spray transfer precautions vary by product | First-pass liver effects and interactions matter; all routes need a medication review |
ACOG notes that nonoral routes may pose less clot risk than pills. Much of the route comparison comes from observational research, so it is not proof that a patch is risk-free or suitable after a clot or stroke.
Ask how your clot history, migraine pattern, blood pressure, other conditions, and preferences affect the choice. Follow the exact instructions for patch adhesion, gel or spray transfer precautions, and missed applications.
Hormone therapy versus hormonal birth control
Menopausal hormone therapy is not birth control.
You can still ovulate and get pregnant during perimenopause, sometimes at a time you do not expect.
If pregnancy would be a problem, you need a contraception plan alongside hormone therapy or in place of it.
Combined hormonal contraceptives and menopausal hormone therapy use different formulations and regimens; a simple dose comparison across products can be misleading. Some clinicians use them for women who need cycle control and contraception together.
They may also ease hot flashes and heavy bleeding.
A clinician must assess contraceptive eligibility separately, including age, smoking, migraine with aura, blood pressure, and clot history. A restriction for combined hormonal contraception does not automatically apply identically to every menopausal hormone product.
Worth asking: Some women switch from birth control to menopausal hormone therapy around the time they reach menopause. Ask your clinician whether a switch would be part of your plan and how you would know when the time comes.
Benefits, side effects, and factors affecting suitability
Benefits
The 2022 Menopause Society position statement describes a generally favorable benefit-risk balance for bothersome hot flashes or prevention of bone loss in women younger than 60 or within 10 years of menopause onset who have no contraindications. This is not a blanket safety guarantee or a reason for someone without symptoms to start treatment.
Common side effects
Breast tenderness, bloating, headaches, nausea, spotting, and mood changes are the usual ones. Progestogens can cause drowsiness or mood changes in some women.
Tell the prescriber about side effects; changes in formulation, route, or regimen may help. Do not change or omit the endometrial-protection component on your own.
Risks to understand clearly
- Blood clots. Oral estrogen raises the risk of clots in the legs and lungs. Skin forms look lower-risk in observational research.
- Stroke. Risk may rise slightly with oral therapy, especially in older women or those further past menopause.
- Breast cancer. Long-term follow-up of the Women’s Health Initiative randomized trials found increased breast cancer incidence with the specific conjugated-estrogen plus medroxyprogesterone regimen studied, but lower incidence with conjugated estrogen alone in participants with prior hysterectomy. These were postmenopausal populations and specific regimens, not proof that every estrogen-only product lowers risk or that every combination has identical effects. Duration and personal history matter.
- Endometrial cancer. Estrogen without a progestogen in a woman with a uterus raises this risk. That is the reason for the pairing.
- Gallbladder disease. Oral estrogen is linked to a higher risk.
Ask about absolute risk: the estimated number of additional events among people with a history like yours over a defined period. Broad statements that risk is small can hide meaningful differences between individuals.
What the FDA changed
The FDA requested labeling revisions in November 2025 and approved changes for an initial group of products in February 2026. Additional products have since been updated. See the FDA list of products with revised prescribing information.
The FDA explains that removing certain risk statements from boxed warnings does not remove cardiovascular and breast cancer risks from other labeling sections. It did not request removal of the endometrial-cancer boxed warning for systemic estrogen-alone products.
Check the current label for the exact formulation. Updated warning placement does not establish that treatment is safe for everyone. Information in this guide was checked November 3, 2026.
Factors that can make it a poor fit
Systemic therapy is generally unsuitable with certain cancer, clot, cardiovascular, liver, or unexplained-bleeding histories; the product label and specialist assessment determine the details. These systemic-therapy considerations should not be automatically applied as identical rules for low-dose local vaginal treatment. A strong family history, high blood pressure, diabetes, and smoking change the conversation, though they do not always rule treatment out.
FDA-approved “bioidentical” hormones versus compounded preparations
Bioidentical means a hormone is chemically identical to one your body makes. Marketing often leaves out that several FDA-approved products already fit this description.
Estradiol patches, gels, and tablets are examples, and so are micronized progesterone capsules.
These products were tested for safety, dose consistency, and quality.
Compounded hormones are mixed by a pharmacy for one patient, often as creams, troches, or pellets. The FDA does not review them for safety, effectiveness, or quality, and doses can vary from batch to batch.
Pellets are not FDA-approved for menopause.
Some sellers pitch compounded products as a way to “balance” hormones based on saliva or blood tests. ACOG does not recommend adjunct hormone tests for prescribing or dosing compounded menopausal hormones, because supporting data are limited. This differs from a clinician ordering a test for another specific diagnostic question.
If you are thinking about a compounded product, ask why an approved one would not work for you. A real reason can exist, such as an allergy to an ingredient.
The word natural does not establish safety or justify choosing a compounded preparation over an appropriate approved option.
For example, Prometrium capsules contain peanut oil and are contraindicated in people allergic to peanuts. A pharmacist should check the ingredients of the exact product offered.
Be careful with unregulated “natural” supplements as well.
Many have never been shown to work, and some interact with medicines.
ACOG recommends FDA-approved menopausal hormone therapy over routine use of compounded preparations when appropriate approved formulations exist. Approval does not remove side effects or contraindications.
Follow-up, bleeding changes, and when to contact a clinician
Agree on follow-up before starting. NICE recommends review at three months and annually thereafter, with earlier review for problems. The schedule also depends on the treatment, symptom response, and individual monitoring needs. Keep age- and risk-appropriate screening up to date.
Bleeding can be confusing because perimenopause already causes irregular bleeding. Spotting in the first few months of therapy is common.
ACOG states that persistent or unscheduled bleeding after starting menopausal hormone therapy warrants evaluation. Ask what bleeding is expected with your particular regimen and when to report it. Do not wait for a routine review if bleeding is heavy or concerning.
Contact a clinician if you notice any of these:
- Heavy bleeding that soaks through protection every hour or two
- Bleeding that lasts much longer than it used to
- Bleeding after 12 months without periods
- Bleeding that starts after a long stretch of none, or after sex
- A new breast lump or nipple discharge
Call 911 for sudden chest pain, trouble breathing, stroke symptoms such as sudden weakness or difficulty speaking, or a sudden severe headache. New swelling or pain in one leg needs urgent medical assessment. Heavy bleeding accompanied by fainting, marked dizziness, chest pain, or shortness of breath also needs emergency care; do not wait to meet a time or pad-count threshold. ACOG explains emergency warning signs associated with abnormal bleeding.
Appointment checklist: questions to ask
Bring whatever symptom and bleeding notes you have; do not delay care to complete a fixed tracking period. Bring a list of your medicines and supplements too, plus what you know about your family history of cancer, clots, and heart disease.
- Based on my symptoms and history, is hormone therapy a reasonable option for me now?
- What else could be causing these symptoms, and should I have any tests first?
- Which type and route would you consider for me, and why?
- Do I need a progestogen, and if so, which kind and why?
- How would this affect my need for contraception?
- What are my personal risks for clots, stroke, and breast cancer?
- Is my breast screening up to date, and do I need anything else beforehand?
- What side effects should I expect, and which ones mean I should call you?
- When will we check whether it is working, and what happens if it is not?
- What nonhormonal options are available?
- If I am interested in a compounded product, why would it be better than an approved one?
- How long should I plan to use this, and when will we reassess?
Tip: Copy this list into your phone notes before the visit so you can read straight from it.
If you need help finding a clinician with menopause expertise, the Menopause Society offers a practitioner directory. A listing does not replace checking a professional’s credentials, services, availability, and insurance participation.
FAQs
Hormone testing
ACOG explains that routine hormone testing is not recommended before starting therapy for typical menopausal symptoms. NICE specifies clinical identification without routine laboratory testing for otherwise healthy people aged 45 or older with typical symptoms and cycle changes.
Hormone levels swing from day to day in perimenopause, so a single blood test can look normal on the wrong day.
Younger age, especially under 40, can change the testing approach. Testing for another suspected condition, such as thyroid disease or anemia, is a separate question. Do not stop contraception to obtain a hormone test without clinical advice.
Starting before menopause
You can start before menopause if symptoms are bothersome and you and your clinician agree it suits you. An earlier start means the plan has to account for contraception, irregular bleeding, and the chance that you will adjust things over time.
Evidence specific to perimenopause is more limited than evidence for postmenopause.
Treatment duration
No single answer fits everyone. Current guidance has moved away from a strict time limit.
Most clinicians reassess on a regular schedule and aim for the lowest effective approach for your goals and risks.
Some women stop after a few years, and others stay on treatment longer after talking through the tradeoffs. Hot flashes can return after stopping. Ask how to stop or reduce therapy; tapering has not been established as universally better than stopping without a taper.
Vaginal estrogen risks
Low-dose vaginal products produce much lower blood levels than pills or patches, so the risk picture differs. If you have a history of breast cancer, tell your clinician, because that decision usually includes your cancer care team.
Heart disease and dementia
Hormone therapy is not approved to prevent heart disease or dementia, and it should not be started for those reasons.
Results
No one can promise a specific result. Some women feel better quickly, some need changes, and some stop because of side effects.
Sources and Further Reading
- The Menopause Society: Hormone therapy
- The Menopause Society: Perimenopause
- 2022 hormone therapy position statement
- ACOG 2026 guideline: Vasomotor, sleep, and mood symptoms
- ACOG: Hormone therapy for menopause
- ACOG: Compounded bioidentical menopausal hormone therapy
- FDA: Hormone therapy and current labeling changes
- FDA: Products with updated prescribing information
- WHI randomized trials: Long-term breast cancer findings
- NICE NG23: Menopause identification and management
- Prometrium prescribing information
This article offers general information and does not replace medical advice. Treatment choices depend on your personal health history.